Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I TSU-68 (orantinib) + carboplatin + paclitaxel in advanced NSCLC
jRCT2080221286Phase 1
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of orantinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
orantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221286.